You have 9 free searches left this month | for more free features.

City

Helsinki (1)

Kuopio (1)

Oulu (1)

San Antonio (1)

Tampere (1)

Turku (1)

Condition

Acute Myeloid Leukemia (1)

Carcinoma Colon (1)

Carcinoma, Renal Cell (1)

Chronic Myelomonocytic Leukemia (1)

Myelodysplastic Syndromes (1)

Non-small Cell Lung Cancer (1)

Relapsed/Refractory AML (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Withdrawn (1)

Sign in for free

Phase

phase 1/phase 2 (2)

phase 1 (1)

Sponsor

Faron Pharmaceuticals Ltd (2)

The University of Texas Health Science Center at San Antonio (1)

Collaborator

Faron Pharmaceuticals Ltd (1)

Intervention

bexmarilimab (2)

azacitidine (1)

bexmarilimab (fp-1305) (1)

pembrolizumab (1)

venetoclax (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (3)

bexmarilimab

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

NSCLC Trial in San Antonio (bexmarilimab (FP-1305), Pembrolizumab)

Not yet recruiting

Non-small Cell Lung Cancer

bexmarilimab (FP-1305)
Pembrolizumab

San Antonio, Texas

Mays Cancer Center, UT Health San Antonio

May 13, 2022

Carcinoma, Renal Cell, Carcinoma Colon Trial in Turku (bexmarilimab)

Withdrawn

Carcinoma, Renal Cell
Carcinoma Colon

bexmarilimab

Turku, Finland

Turku University Hospital

May 5, 2022

Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, MDS Trial in Finland (Bexmarilimab, Azacitidine, Venetoclax)

Recruiting

Acute Myeloid Leukemia
+3 more

Bexmarilimab
+2 more

Helsinki, Finland
+3 more

Jun 29, 2022